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m.GlaserAbstract Diffuse intrinsic pontine glioma (DIPG) has a dismal prognosis with no chemother-
apy regimen so far resulting in any signiﬁcant improvement over standard radiotherapy. In
this trial, a prolonged regimen (21/28 d) of temozolomide was studied with the aim of over-
coming O6-methylguanine methyltransferase (MGMT) mediated resistance.
Forty-three patients with a deﬁned clinico-radiological diagnosis of DIPG received radiother-
apy and concomitant temozolomide (75 mg/m2) after which up to 12 courses of 21 d of adju-
vant temozolomide (75–100 mg/m2) were given 4 weekly. The trial used a 2-stage design and
passed interim analysis.ed by Elsevier Ltd.
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S. Bailey et al. / European Journal of Cancer 49 (2013) 3856–3862 3857At diagnosis median age was 8 years (2–20 years), 81% had cranial nerve abnormalities, 76%
ataxia and 57% long tract signs. Median Karnofsky/Lansky score was 80 (10–100). Patients
received a median of three courses of adjuvant temozolomide, ﬁve received all 12 courses
and seven did not start adjuvant treatment. Three patients were withdrawn from study treat-
ment due to haematological toxicity and 10 had a dose reduction. No other signiﬁcant toxicity
related to temozolomide was noted. Overall survival (OS) (95% conﬁdence interval (CI)) was
56% (40%, 69%) at 9 months, 35% (21%, 49%) at 1 year and 17% (7%, 30%) at 2 years. Median
survival was 9.5 months (range 7.5–11.4 months). There were ﬁve 2-year survivors with a med-
ian age of 13.6 years at diagnosis.
This trial demonstrated no survival beneﬁt of the addition of dose dense temozolomide, to
standard radiotherapy in children with classical DIPG. However, a subgroup of adolescent
DIPG patients did have a prolonged survival, which needs further exploration.
 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-SA license.1. Introduction
Diﬀuse intrinsic pontine glioma (DIPG) is a devastat-
ing diagnosis for which there is no eﬀective treatment
strategy that results in cure. Nearly 90% of children
are dead within 18 months of diagnosis and an average
median survival of around 9 months is reported in a
number of series [1–3].
Radiotherapy is the only treatment that has shown any
degree of eﬃcacy [4] but this usually merely delays the
inevitable progression of the tumour. Hyperfractionation
and increased doses of up to 78 Gy have had no additional
eﬀect [5–8]. A number of chemotherapeutic approaches
have also been tried with limited or no eﬀect. These
have included radiosensitisers such as carboplatin [9–11],
standardchemotherapy suchas etoposide (oral and intrave-
nous) [12,13], vincristine and high dose chemotherapy such
as busulfan and thiotepa with stem cell support [14,15].
Temozolomide is an oral alkylating agent which
crosses the blood brain barrier [16] and is used widely
in the treatment of high grade gliomas, both in adults
and children. It has been shown to be well tolerated
and prolongs survival in glioblastoma [17]. Disappoint-
ingly, given in the standard way (alongside radiotherapy
and subsequently for ﬁve out of every 28 d) this beneﬁt
has not been seen in DIPG in children [18–21] with med-
ian survival time of 11.7 and 9.6 months similar to his-
torical controls treated with radiotherapy alone [1].
Temozolomide results in the depletion of O6-methyl-
guanine methyltransferase (MGMT), a DNA repair pro-
tein. Administration with extended low dose schedules
has been demonstrated in peripheral blood mononuclear
cells to result in greater depletion of MGMT and thus a
greater retention of O6-methylguanine in DNA that pro-
duces the predominant cytotoxic eﬀect [22,23] as well as
less time for protein replenishment to occur in between
doses of temozolomide. This was extrapolated and an
assumption made that the same eﬀect may be seen in
tumour cells. A prolonged dosing regime has been shown
to be feasible and safe in a paediatric population [24].
This trial studied the eﬀect of prolonged dose dense
temozolomide both post radiotherapy (21/28 d) as wellas concomitantly during radiotherapy (42 d) in children
with newly diagnosed DIPG.2. Patients and methods
2.1. Eligibility
Children and young people aged 2–21 years with a
newly diagnosed diﬀuse intrinsic lesion centred in the
pons and compatible with radiological criteria of DIPG
on MRI imaging were eligible for the study. In addition,
a clinical history of less than 6 months and the presence
of at least one of the following (i) cranial nerve deﬁcit,
(ii) long tract signs or (iii) ataxia were required. The
patients also were required to have a Karnofsky Perfor-
mance Status or a Lansky play score of greater than or
equal to 60 unless the reason for decrease in status was a
direct result of neurological involvement of the brain-
stem glioma, a life expectancy of more than 12 weeks
and adequate haematological, renal and hepatic func-
tion. Patients were not eligible for the study if they
had a focal lesion of the brainstem, a predominantly
exophytic tumour, had received previous chemotherapy
or radiotherapy or had a condition which would have
interfered with oral medication intake. Written
informed parental consent (and assent for older chil-
dren) was taken and the study was approved by a mul-
ticentre research ethics committee (Derby 1). Biopsy was
not mandated for this study.2.2. Treatment
This was a single arm open-label phase II study of
concurrent and adjuvant single agent temozolomide
alongside initial focal radiotherapy of 54 Gy given in
30 fractions over a 6 week period. An induction course
of temozolomide was administered at an initial dose of
75 mg/m2 daily alongside radiotherapy (42 d). Follow-
ing a minimum 4 week break after radiotherapy tem-
ozolomide was administered daily for 21 consecutive
days out of every 28 at a starting dose of 75 mg/m2/d.
After two cycles this dose was increased to 100 mg/m2/d
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providing there was no clinical progression (Fig. 1).
2.3. Response evaluation
Response was evaluated (by the local team) clinically
based on neurological examination (+2 = deﬁnitely bet-
ter, +1 = possibly better, 0 = unchanged, 1 = possibly
worse, 2 = deﬁnitely worse) and radiologically based
on the RECIST criteria as outlined below: The RECIST
criteria system was chosen as this was the most widely
used system at the time of the trial.
 CR (complete response) – disappearance of all tumour
 PR (partial response) – at least a 30% decrease in the
sum of the longest diameter (LD) of target lesions,
taking as a reference the baseline sum LD and no
new lesions.
 SD (stable disease) – neither suﬃcient shrinkage to
qualify for PR nor suﬃcient increase to qualify for
progressive disease (PD), taking as reference the
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Fig. 1. Overall and progression free survival of children treated on the diﬀ PD (progressive disease) – at least a 20% increase in
the sum of the LD of target lesions, taking as refer-
ence the smallest sum LD recorded since the treat-
ment started or the appearance of one or more new
lesions.
No patient was withdrawn from the study purely on
radiological grounds.
2.4. Quality of life
It was intended to assess quality of life and steroid
administration as part of the study. The quality of life
assessment (QoL) was planned to be performed prior
to radiotherapy, at the beginning of adjuvant temozolo-
mide and prior to each subsequent three cycles of tem-
ozolomide. The health utilities index (HUI) [25] and
strengths and diﬃculties questionnaire (SDQ) [26] were
used. Data collection from centres however was subop-
timal for both QoL and steroid administration and inad-
equate for meaningful analysis and therefore cannot be
reported reliably.onths)
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  7%
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This trial was originally designed as a Case-Morgan
design [27]. This method was chosen to allow the trial
to stop early for futility. It was a single arm study, test-
ing a null hypothesis of 50% overall survival at 9 months
against an alternate hypothesis of 70%. The level of sig-
niﬁcance for the study was set at a 1-tailed alpha of 0.05.
There was one intermediate analysis for futility, which
did not result in the trial stopping. The primary hypoth-
esis test in the study was a 1-tailed test of the survival at
9 months. No other hypothesis testing was carried out –
where appropriate, point estimates are presented with 2-
tailed 95% conﬁdence intervals.
Overall survival has been calculated as time from
study entry to death from any cause, with patients cen-
sored at date last seen if lost to follow up. Time to treat-
ment failure has been calculated as time from study
entry to stopping temozolomide for any reason (except
reaching the end of the maintenance course without pro-
gression) or death.able 1
easons for withdrawal of temozolomide.3. Results
3.1. Patient characteristics
Between February 2008 and July 2010, 43 patients
from 16 centres with clinically and radiologically diag-
nosed DIPG were registered and treated according to
the protocol described above (CCLG CNS 2007/4).
The median age at presentation was 8 years (2–
20 years) and the male: female ratio was 24:19. Eighty-
one percent of patients presented with cranial nerve
abnormalities, 76% with ataxia and 57% with long tract
signs. Median Karnofsky/Lansky score was 80 (mean
79; range 10–100). The median time from onset of symp-
toms to starting treatment was 32 d, range 9–194, (sec-
ond highest 130).
Thirty-eight patients received the full course of induc-
tion temozolomide, and a further three had dose reduc-
tions (two due to thrombocytopenia and one due to
abdominal obstruction). In two cases it is unknown
whether the full induction course was received. One
child stopped radiotherapy after 18 Gy due to the need
for surgical intervention (Ventriculoperitoneal shunt).
Two others had short interruptions but received the
total dose. Patients received a median of three courses
of maintenance temozolomide, ﬁve received all 12
courses and seven did not start maintenance (six due
to progression and one due to patient choice). Three
patients were withdrawn from study treatment due to
haematological toxicity and 10 had a dose reduction
on at least one course. The most common grade 3/4 tox-
icities associated with induction temozolomide were:
lymphopaenia (45% of patients with at least one epi-
sode), neutropaenia (12%), thrombocytopaenia (10%),infection (10%), leucopaenia (8%) and nausea (8%).
Grade 3/4 toxicity associated with radiotherapy/tem-
ozolomide was very rare. One case each of ataxia, head-
aches/vomiting (both same patient) and elevated alanine
aminotransferase (ALT). The most common grade 3/4
toxicities associated with maintenance temozolomide
were: lymphopaenia (68% of patients with at least one
episode), infection (24%), leukocytopaenia (21%) neu-
tropaenia (15%), thrombocytopaenia (12%) and fatigue
(12%). The reasons for withdrawal from treatment are
detailed in Table 1.
Based on the post radiotherapy assessment
(RECIST), 11 children had partial response (PR), 26
stable disease (SD), four progressive disease (PD), and
two not available. Seven children had an increased
tumour size on their post radiotherapy scan (four PD
and three SD on RECIST criteria). Of these, four had
progressive disease by RECIST criteria and three stable
disease. Of these seven children the survival time ranged
from 87 to 420 days (median 212 d) that was not statis-
tically signiﬁcant from the cohort as a whole.
Overall survival (95% conﬁdence interval (CI)) was
56% (40%, 69%) at 9 months. The comparison against
the null hypothesis rate of 50% gave a 1-tailed p value
of 0.23. A likelihood Bayesian approach suggested that
there was a 77% chance that OS was >50% at 9 months.
OS at 1 year was 0.35 (0.21, 0.49), and 0.17 (0.07, 0.30)
at 2 years. Median survival was 9.5 months (7.5, 11.4)
(Fig. 1). Median time to treatment failure (stopping tem-
ozolomide usually due to progression) was 168 d, with
88% of patients either dying or withdrawing from treat-
ment by 1 year. Six patients had not died as at last fol-
low up. These had been followed up for between
14 months and 3 years. All were last recorded as having
had stable disease without additional treatment. There
were ﬁve 2 year survivors with ages of 9, 12, 13, 16T
R
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the whole study median age of 8 years. One patient
received two maintenance courses, one 6 courses and
three all 12 courses. One had a partial response after
radiotherapy, the other four had stable disease. There
were no other unusual clinical or radiological features
apart from age to predict that these children would be
alive at 2 years.
4. Discussion
This study treating children and young people with
DIPG with a prolonged dose dense temozolomide regi-
men in addition to focal radiotherapy showed no overall
survival beneﬁt over radiotherapy alone [4]. The median
survival of 9.5 months is compatible with that reported
in other trials in this disease [1,3,18–21]. This study also
showed no improvement in 1 year survival, however the
2 year survival was 17% and better than the majority of
reported series. This must be treated with caution as the
numbers are small and may not be a true reﬂection of a
deﬁnite survival advantage. Interestingly, the group of
patients surviving for 2 years or longer has an older
median age (13.6, range 9–18 years) than a typical DIPG
patient. It is already known that children less than
3 years of age tend to have a better outlook [28], and
it could be questioned as to whether there is another
subgroup of older adolescent DIPG patients that may
have a better outcome, possibly due to a diﬀerence in
underlying biology. This raises important questions as
to whether age stratiﬁcation should be considered in
DIPG trials to ensure an adequate sample size to iden-
tify possible age related prognostic factors.
The prolonged temozolomide regime was well toler-
ated with the main toxicity being haematological which
resulted in three children withdrawing from treatment
for this reason and 10 children having at least one dose
reduction. There were no treatment related deaths and
this regime did not have any greater toxicity than the
5/28 d regime [18–20]. Although, a prolonged adminis-
tration schedule may make the drug more eﬀective in
maintaining depleted MGMT, our results did not sup-
port this treatment strategy. An on-going US trial with
mandatory biopsy and biological analysis prior to treat-
ment where temozolomide will be given in MGMT
hypermethylated tumours, may help to answer this
question [29,30].
A recently reported study in adults with recurrent
high grade glioma, suggested a lower activity of this
dose dense schedule compared to standard 5 days
despite the strong theoretical rationale of using a pro-
longed dosing schedule [31]. It is possible although unli-
kely that high MGMT expression or other resistance
mechanisms account for this lack of response but as
biopsy was not mandated for this study this could notbe tested. However in a study by Zarghooni [32] MGMT
expression was not seen in DIPG patient material.
Another explanation of lack of activity in DIPG may
be poor drug delivery and it possible that temozolomide,
although known to penetrate the central nervous sys-
tem, fails to achieve suﬃcient tumour concentrations
due to a greater integrity of the blood brain barrier in
a typical DIPG. This is suggested by the lack of contrast
enhancement in the majority of these tumours. A num-
ber of newer delivery strategies have been suggested
such as convection-enhanced delivery of chemothera-
peutic agents [33,34].
To date no novel therapeutic strategies have been
shown to oﬀer a survival beneﬁt over and above stan-
dard radiotherapy (reviewed by Hargrave et al. [1] and
Jansen et al. [3]). The reasons for this may include;
lack of biological knowledge due to limited access to
tumour samples, lack of DIPG preclinical models,
tumour heterogeneity and poor drug delivery [35].
However, these issues are starting to be addressed
and a better understanding of the molecular biology
of DIPG is now emerging [32,36], with speciﬁc muta-
tions in histone H3 characterising pontine glioma [37–
39]. There is now a drive to develop appropriate cell
culture and animal models to assist in developing
DIPG speciﬁc targeted therapies.
The issue of biopsy of DIPG should now be reconsid-
ered as part of future clinical trials as this would allow
both prospective patient stratiﬁcation/enrichment if a
target exists and also retrospective analysis of patients
based on biology to identify and explain subgroups of
patients with longer survival that may beneﬁt from a
given therapy.
Unless further evidence becomes available, single
agent temozolomide cannot be recommended for rou-
tine use in children with DIPG and its use in adolescents
and in combination with other agents requires further
evaluation. Future DIPG studies should consider possi-
ble emerging clinical and biological prognostic sub-
groups and be stratiﬁed and powered accordingly.Conﬂict of interest statement
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